In addition, targeted therapies using tyrosine-kinase inhibitors, MEK inhibitors, and PI3K/mTOR/Akt inhibitors are currently being tested in several ovarian cancer subtypes [155]. The gene discussed is AKT1; the disease is ovarian cancer.